Genetic and cellular techniques emerge as promising modalities for the treatment of diabetic foot syndrome

Two patient groups potentially to benefit most from these novel methods are patients with critical lower limb ischemia (CLLI) in whom angiosurgery is not indicated, and patients with trophic ulcers resistant to conventional therapy. A series of clinical trials has shown positive effects of transferr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vladimir Iosifovich Konenkov, Vadim Valerievich Klimontov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2014
Materias:	diabetic foot syndrome critical ischemia ulcer healing, angiogenesis, gene transfer growth factors cellular therapy Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/315807eea5c14339bfd20b2dea34a56a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:315807eea5c14339bfd20b2dea34a56a
record_format	dspace
spelling	oai:doaj.org-article:315807eea5c14339bfd20b2dea34a56a2021-11-14T09:00:18ZGenetic and cellular techniques emerge as promising modalities for the treatment of diabetic foot syndrome2072-03512072-037810.14341/DM2014163-69https://doaj.org/article/315807eea5c14339bfd20b2dea34a56a2014-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6340https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Two patient groups potentially to benefit most from these novel methods are patients with critical lower limb ischemia (CLLI) in whom angiosurgery is not indicated, and patients with trophic ulcers resistant to conventional therapy. A series of clinical trials has shown positive effects of transferring VEGF, HIF-1, FGF, PDGF, HGF and certain other growth factor genes to stimulate blood vessel formation and healing of diabetic ulcers. Autologous transplantation of mononuclear bone marrow and peripheral blood cells, endothelial progenitor cells, mesenchymal stem cells and stromal cell of the adipose tissue has also demonstrated its clinical potential in patients with diabetes mellitus and CLLI. Randomized clinical trials report beneficial effects of gene and cell therapy on such surrogate endpoints as ischemic index, rest pain and ulcer healing, though data on amputation rates is controversial. Further studies are necessary to determine optimal dosage and route of administration of biological agents and predictors of their efficacy, as well as long-term safety of these novel treatment modalities.Vladimir Iosifovich KonenkovVadim Valerievich KlimontovEndocrinology Research Centrearticlediabetic foot syndromecritical ischemiaulcer healing, angiogenesis, gene transfergrowth factorscellular therapyNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 17, Iss 1, Pp 63-69 (2014)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetic foot syndrome critical ischemia ulcer healing, angiogenesis, gene transfer growth factors cellular therapy Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetic foot syndrome critical ischemia ulcer healing, angiogenesis, gene transfer growth factors cellular therapy Nutritional diseases. Deficiency diseases RC620-627 Vladimir Iosifovich Konenkov Vadim Valerievich Klimontov Genetic and cellular techniques emerge as promising modalities for the treatment of diabetic foot syndrome
description	Two patient groups potentially to benefit most from these novel methods are patients with critical lower limb ischemia (CLLI) in whom angiosurgery is not indicated, and patients with trophic ulcers resistant to conventional therapy. A series of clinical trials has shown positive effects of transferring VEGF, HIF-1, FGF, PDGF, HGF and certain other growth factor genes to stimulate blood vessel formation and healing of diabetic ulcers. Autologous transplantation of mononuclear bone marrow and peripheral blood cells, endothelial progenitor cells, mesenchymal stem cells and stromal cell of the adipose tissue has also demonstrated its clinical potential in patients with diabetes mellitus and CLLI. Randomized clinical trials report beneficial effects of gene and cell therapy on such surrogate endpoints as ischemic index, rest pain and ulcer healing, though data on amputation rates is controversial. Further studies are necessary to determine optimal dosage and route of administration of biological agents and predictors of their efficacy, as well as long-term safety of these novel treatment modalities.
format	article
author	Vladimir Iosifovich Konenkov Vadim Valerievich Klimontov
author_facet	Vladimir Iosifovich Konenkov Vadim Valerievich Klimontov
author_sort	Vladimir Iosifovich Konenkov
title	Genetic and cellular techniques emerge as promising modalities for the treatment of diabetic foot syndrome
title_short	Genetic and cellular techniques emerge as promising modalities for the treatment of diabetic foot syndrome
title_full	Genetic and cellular techniques emerge as promising modalities for the treatment of diabetic foot syndrome
title_fullStr	Genetic and cellular techniques emerge as promising modalities for the treatment of diabetic foot syndrome
title_full_unstemmed	Genetic and cellular techniques emerge as promising modalities for the treatment of diabetic foot syndrome
title_sort	genetic and cellular techniques emerge as promising modalities for the treatment of diabetic foot syndrome
publisher	Endocrinology Research Centre
publishDate	2014
url	https://doaj.org/article/315807eea5c14339bfd20b2dea34a56a
work_keys_str_mv	AT vladimiriosifovichkonenkov geneticandcellulartechniquesemergeaspromisingmodalitiesforthetreatmentofdiabeticfootsyndrome AT vadimvalerievichklimontov geneticandcellulartechniquesemergeaspromisingmodalitiesforthetreatmentofdiabeticfootsyndrome
_version_	1718429575478771712

Genetic and cellular techniques emerge as promising modalities for the treatment of diabetic foot syndrome

Ejemplares similares